Idorsia Pharmaceuticals Ltd: Idorsia announces changes to Idorsia Executive Committee and Board of Directors

Ad hoc announcement pursuant to Art. 53 LR Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of DirectorsMathieu Simon to stand for re-election to the Board - taking

Related Keywords

Switzerland ,Montreal ,Quebec ,Canada ,France ,San Francisco ,California ,United States ,Chiron ,Centre ,Paris ,France General ,Allschwil ,Switzerland General ,Japan ,Netherlands ,French ,America ,Swiss ,Sandy Mahatme ,Martine Clozel ,Alberto Gimona ,Bart Filius ,Mathieu Simon ,Andrewc Weiss ,Arno Groenewoud ,Jean Paul Clozel ,Peter Kellogg ,Sophie Kornowski ,Srishti Gupta ,Felix Ehrat ,Julien Gander ,University Of Montreal ,Roche Research Prize ,Business Administration ,Business School ,Nyenrode University ,Head Of Investor Relations Corporate Communications ,Audit Committee Of Proqr Therapeutics ,Johnson ,Head Of Global Clinical Development ,Arthurd Little ,Business Development ,Idorsia Pharmaceuticals Ltd ,Swiss Exchange ,Idorsia Ltd ,Roche Ltd ,Idorsia Executive Committee ,University Of California ,Nasdaq ,Paul Clozel ,Lead Independent ,Annual General Meeting ,Chief Executive Officer ,Chief Financial Officer ,Group General Counsel ,Chief Scientific Officer ,Global Clinical Development ,Group General ,Lead Independent Director ,Roche Cardiovascular Drug Discovery ,Technical Innovation ,Pierre Fabre ,Chiron Investments ,Chief Operating Officer ,Audit Committee ,Vice President ,North America ,Investor Relations ,Pharmaceuticals Ltd ,Ihr Portfolio ,